Inhibikase raises ~$93.6M in public offering, advances IKT-001 to Phase 3 PAH trial

Inhibikase Therapeutics, Inc.

Offering of 46.1M shares at $1.45/share and pre-funded warrants for 22.9M shares; net proceeds ~$93.6M.
Underwriters granted 30-day option to purchase up to 10.3M additional shares.
Company amended Series A-1 and B-1 warrants to reflect plan to advance IKT-001 to global pivotal Phase 3 trial in PAH.
Offering expected to close November 24, 2025; shelf registration effective June 27, 2025.
Jefferies, BofA Securities, and Cantor Fitzgerald are representatives of the underwriters.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Inhibikase Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, BofA Securities, Inc. and Cantor Fitzgerald & Co., as representatives of the several underwriters (effective 2025-11-20).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC, BofA Securities, Inc. and Cantor Fitzgerald & Co., as representatives of the several underwriters
Effective: 2025-11-20

Exact text from the filing

On November 20, 2025, Inhibikase Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, BofA Securities, Inc. and Cantor Fitzgerald & Co., as representatives of the several underwriters listed on Schedule A thereto (collectively, the “Underwriters”), relating to an underwritten public offering (the “Offering”) of (i) 46,091,739 shares (the “Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and (ii) in lieu of Common Stock to certain investors, pre-funded warrants to purchase up to an aggregate of 22,873,779 shares of Common Stock (the “Pre-Funded Warrants” and the Common Stock issuable upon exercise of the Pre-Funded Warrants, the “Warrant Shares”).

View on SEC.gov

271 material agreements filed in the last 30 days. Browse all material agreements →

Inhibikase Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-291443

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.